title: [Perspectives of the novel drug divaza in the treatment of chronic cerebral ischemia].
abstract: The present paper reviews preclinical research of divaza, the combination of release-active antibodies to brain-specific 5100 protein and release-active antibodies to endothelial NO-synthase. Preclinical studies have revealed that the specific pharmacological activity of the compounds is retained in the combination, and the components mutually potentiate each other's effects. The previous research have demonstrated high efficacy of divaza in the experimental models of cerebral ischemia and neurodegenerative diseases. Divaza also displays the antihypoxant and antioxidant activity in the animal models of hypoxia by reducing the pathological changes of brain tissue. Significant reduction of the lipid peroxidation process in the affected brain regions can be one of the mechanisms of this effect. In standard experimental models of anxiety and depression, divaza positively influences the psycho-emotional state of animals.
authors.forename: K K
authors.initials: KK
authors.lastname: Tanaeva
authors.forename: Iu L
authors.initials: IuL
authors.lastname: Dugina
authors.forename: E V
authors.initials: EV
authors.lastname: Kachaeva
authors.forename: O I
authors.initials: OI
authors.lastname: Epshteĭn
mesh_terms: D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000188:drug therapy*; D004195:Disease Models, Animal; D015227:Lipid Peroxidation / Q000187:drug effects; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D009418:S100 Proteins / Q000276:immunology* / Q000378:metabolism
chemical_list: D000906:Antibodies; D000975:Antioxidants; D009418:S100 Proteins; C000610361:divaza; D052250:Nitric Oxide Synthase Type III